Skip to main navigation

Topbar Nav

  • Investors & Media
  • Careers
  • Connect

Home

Main navigation

 

Main navigation

  • Our DNA
    • Our DNA - Child
      • Our vision
      • Leadership
      • Responsibility
      • Collaborators
      • Services
      • Our locations
      • BioNTech US
  • How we translate
    • How we translate - Child
      • The BionTech Approach
      • mRNA Therapeutics
      • Engineered Cell Therapies
      • Antibodies
      • Small Molecule Immunomodulators
      • Manufacturing
      • Intellectual property
  • Science
    • Science - Child
      • Individualized cancer medicine
      • Pipeline
      • Platforms
      • Publications
  • For patients
    • For patients - Child
      • Info & Resources
      • Clinical trials
  • COVID-19
    • covid - child
      • COVID-19 Portal
      • COVID-19 Disease
      • mRNA Vaccines
      • Project Lightspeed
      • Frequently asked questions

Topbar Nav

  • Investors & Media
  • Careers
  • Connect
  • Annual Reports

    IR Side Nav

    • Overview
    • Press Releases
    • Events & Presentations
    • Publications
    • SEC Filings
    • ESG
    • Financial Reports
      • Annual Reports
      • Quarterly Reports
    • Financial Calendar
    • Corporate Governance
    • Analyst Coverage
    • Stock Information
      • Share Repurchase Program
    • Shareholder Fraud Warning
    • Annual General Meeting
    • Investor FAQ
    • Media Materials
    • Sign-up for Email Alerts
    Investor Contact Sylke Maas, Ph.D.
    VP Investor Relations & Strategy
    Send Email
    +49 6131 9084-0
    For U.S. Investors:
    Westwicke
    John Woolford
    Send Email
    +1 443 213-0506
    Media Contact Jasmina Alatovic
    Director Global External Communications
    Send Email
    +49 6131 9084-0
    • English
    • German

    Annual Reports

    2021 Reports

    20-F

    BioNTech Annual Report 2021

    BioNTech Group Financial Statements 2021

    2021 Sustainability Report

    2020 Reports

    20-F

    BioNTech Annual Report 2020 (German)

    Sustainability Report 2020

    Nachhaltigkeitsbericht 2020

    2019 Reports

    20-F

    BioNTech Annual Report 2019 (German)

    Before footer menu

    • Information Request
    • RSS Feeds
    Logo

    BioNTech SE
    An der Goldgrube 12
    55131 Mainz
    Germany

     

    T: +49 6131 9084-0

    For questions on logistics,
    handling or other issues:
    service@biontech.de

    For any other questions, please
    use our contact form at
    connect.biontech.de

    We aspire to utilize the full potential of the immune system to fight cancer and infectious diseases

    02. Footer Column2 Links

    • Connect
    • Our DNA
    • How We Translate
    • Science
    • For Patients
    • Investors & Media
    • Careers

    03. Footer Column3 Links

    • Imprint
    • Terms Of Use
    • General Terms and Conditions
    • General Conditions Of Purchase
    • Data Privacy Statement
    • Data Processing Terms Business Partners
    • Adverse Event Reporting
    • Cookie Settings

    Follow us

       

    © Copyright BioNTech SE . All Rights Reserved.
     
    Our Vision
    Our vision: individualize cancer medicine
    Leadership
    Meet our leadership team
    Collaborators
    Get to know our partners
    Our Locations
    Learn about our services
    The BioNTech approach
    How we approach individualized cancer medicine
    mRNA Therapeutics
    Why mRNA represents a disruptive new drug class
    Antibodies
    Beyond mRNA: Expanding therapeutics with our antibody discovery engines
    Manufacturing
    Manufacturing our own therapeutics
    Pipeline
    Explore our pipeline
    Platforms
    Tour our platforms that produce individually-tailored therapeutics
    Publications
    Browse our research publications
    Info & Resources
    Our Mission: broaden the therapeutic universe to benefit patients
    Clinical trials
    Clinical trials currently ongoing